Abbott Laboratories (ABT) Set to Announce Quarterly Earnings on Wednesday
Abbott Laboratories (NYSE:ABT) is scheduled to announce its Q313 earnings results on Wednesday, October 16th. Analysts expect the company to announce earnings of $0.52 per share and revenue of $5.46 billion for the quarter. Abbott Laboratories has set its FY13 guidance at $1.98-2.04 EPS.Investors that wish to register for the company’s conference call can do so using this link.
Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Wednesday, July 17th. The company reported $0.46 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.44 by $0.02. The company had revenue of $5.45 billion for the quarter, compared to the consensus estimate of $5.53 billion. During the same quarter last year, the company posted $1.23 earnings per share. Abbott Laboratories’s revenue was up 2.5% compared to the same quarter last year. On average, analysts expect Abbott Laboratories to post $2.00 EPS for the current fiscal year and $2.23 EPS for the next fiscal year.
Shares of Abbott Laboratories (NYSE:ABT) opened at 34.00 on Tuesday. Abbott Laboratories has a one year low of $30.0451 and a one year high of $38.77. The stock’s 50-day moving average is $34.00 and its 200-day moving average is $35.71. The company has a market cap of $52.840 billion and a P/E ratio of 13.47.
The company also recently announced a quarterly dividend, which is scheduled for Friday, November 15th. Stockholders of record on Tuesday, October 15th will be paid a dividend of $0.14 per share. This represents a $0.56 annualized dividend and a dividend yield of 1.65%. The ex-dividend date is Thursday, October 10th.
ABT has been the subject of a number of recent research reports. Analysts at Stifel Nicolaus cut their price target on shares of Abbott Laboratories from $44.00 to $40.00 in a research note to investors on Monday, October 7th. They now have a “buy” rating on the stock. On a related note, analysts at Jefferies Group reiterated a “buy” rating on shares of Abbott Laboratories in a research note to investors on Wednesday, September 4th. They now have a $44.00 price target on the stock, down previously from $46.00. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Abbott Laboratories in a research note to investors on Friday, August 30th. They now have a $35.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and ten have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $37.85.
Abbott Laboratories (NYSE:ABT), is engaged in the discovery, development, manufacture, and sale of a portfolio of science-based health care products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.